![](/img/cover-not-exists.png)
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
Reich, Kristian, Armstrong, April W., Foley, Peter, Song, Michael, Wasfi, Yasmine, Randazzo, Bruce, Li, Shu, Shen, Y.-K., Gordon, Kenneth B.Volume:
76
Language:
english
Journal:
Journal of the American Academy of Dermatology
DOI:
10.1016/j.jaad.2016.11.042
Date:
March, 2017
File:
PDF, 709 KB
english, 2017